@article{14a26c9bf6164f8fa0f1167366b95741,
title = "Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies",
abstract = "Type 2 diabetes (T2D) is a progressive disease, with many individuals eventually requiring basal insulin therapy to maintain glycaemic control. However, there exists considerable therapeutic inertia to the prompt initiation and optimal titration of basal insulin therapy due to barriers that include fear of injections, hypoglycaemia, weight gain, and burdensome regimens. Hypoglycaemia is thought to be a major barrier to optimal glycaemic control and is associated with significant morbidity and mortality. Newer second-generation basal insulin analogues provide comparable glycaemic control with lower risk of hypoglycaemia compared with first-generation basal insulin analogues. The present review article discusses clinical evidence for one such second-generation basal insulin analogue, insulin glargine 300 U/mL (Gla-300), in the context of hypothetical case studies that are representative of individuals who may attend routine clinical practice. These case studies discuss individualised treatment needs for people with T2D who are insulin-na{\"i}ve or pre-treated. Clinical characteristics such as older age, frequent nocturnal hypoglycaemia, and renal impairment, which are known risk factors for hypoglycaemia, are also considered.",
keywords = "Basal insulin analogues, Glycaemic control, Hypoglycaemia, Insulin glargine 300 U/mL, Type 2 diabetes",
author = "Harris, {Stewart B.} and Parente, {Erika B.} and Janaka Karalliedde",
note = "Funding Information: Support for this work and the journal{\textquoteright}s Rapid Service Fee was provided by Sanofi. Funding Information: Support for this work and the journal{\textquoteright}s Rapid Service Fee was provided by Sanofi. Medical writing and editorial assistance was provided by Hannah Brown, PhD, and Simon Rees, PhD, of Fishawack Communications Ltd, and was funded by Sanofi. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Stewart B. Harris, Erika B. Parente and Janaka Karalliedde contributed to interpretation of published data to develop the article content, reviewed all drafts of the article and approved the final version for submission. Stewart B. Harris—Consultant: Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Sanofi; Research support: Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, Janssen, Novo Nordisk, Sanofi. Erika B. Parente—Received lecture honorariums and consulting fees from Eli Lilly, Abbott, AstraZeneca, Sanofi, Boehringer Ingelheim and is an advisory board member of Sanofi. Janaka Karalliedde—Served on scientific advisory boards and received honoraria or consulting fees from Eli Lilly, Novo Nordisk, Sanofi, Napp, AstraZeneca, Boehringer Ingelheim; and has received grants/research support from Sanofi and AstraZeneca. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = may,
doi = "10.1007/s13300-022-01247-7",
language = "English",
volume = "13",
pages = "913--930",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer Publishing Company",
number = "5",
}
